Citation Impact
Citing Papers
β-Arrestin-dependent signaling and trafficking of 7-transmembrane receptors is reciprocally regulated by the deubiquitinase USP33 and the E3 ligase Mdm2
2009 StandoutNobel
High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model
2017
Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
2017
Identification of a Primary Target of Thalidomide Teratogenicity
2010 StandoutScience
CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date
2016
Similar Nucleotide Excision Repair Capacity in Melanocytes and Melanoma Cells
2010 StandoutNobel
Designed protein logic to target cells with precise combinations of surface antigens
2020 StandoutScienceNobel
Ionizing Radiation Induces ATM-independent Degradation of p21Cip1 in Transformed Cells
2009
Contribution of olfactory neural stem cells to tissue maintenance and regeneration
2007
CDK Inhibitor p21 Is Degraded by a Proliferating Cell Nuclear Antigen-coupled Cul4-DDB1Cdt2 Pathway during S Phase and after UV Irradiation
2008
Engineered receptors for soluble cellular communication and disease sensing
2024 StandoutNatureNobel
Cancer immunotherapy beyond immune checkpoint inhibitors
2018
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
Global Manufacturing of CAR T Cell Therapy
2017
The promise and challenge of therapeutic genome editing
2020 StandoutNatureNobel
Engineering precision nanoparticles for drug delivery
2020 Standout
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
2017
A view on drug resistance in cancer
2019 StandoutNature
Cytokines in CAR T Cell–Associated Neurotoxicity
2020
Ferroptosis as a p53-mediated activity during tumour suppression
2015 StandoutNature
A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity
2020
Regulatory Mechanisms of Tumor Suppressor P16INK4Aand Their Relevance to Cancer
2011
Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting
2019
Phosphatase and tensin homolog deleted on chromosome 10 regulates sensory cell proliferation and differentiation of hair bundles in the mammalian cochlea
2010 StandoutNobel
Enhancement of proteasomal function protects against cardiac proteinopathy and ischemia/reperfusion injury in mice
2011
Cell Signaling by Receptor Tyrosine Kinases
2010 Standout
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Hypoxia-inducible Factor Prolyl-4-hydroxylase PHD2 Protein Abundance Depends on Integral Membrane Anchoring of FKBP38
2009
Clinical lessons learned from the first leg of the CAR T cell journey
2019
Transforming Growth Factor-β Signaling in Immunity and Cancer
2019 Standout
Hallmarks of aging: An expanding universe
2023 Standout
APC/CCdc20 Controls the Ubiquitin-Mediated Degradation of p21 in Prometaphase
2007
The LIMD1 protein bridges an association between the prolyl hydroxylases and VHL to repress HIF-1 activity
2012 StandoutNobel
Injury Induces Endogenous Reprogramming and Dedifferentiation of Neuronal Progenitors to Multipotency
2017
Cytokine release syndrome
2018
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
2011 StandoutNature
Hepatocellular carcinoma
2021 Standout
CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
2019 StandoutNobel
Mdm2-mediated ubiquitylation: p53 and beyond
2009
Cell cycle regulation in hair cell development and regeneration in the mouse cochlea
2008
Amniotic fluid stabilized lipid nanoparticles for in utero intra-amniotic mRNA delivery
2021 StandoutNobel
CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
2018
Engineering interferons and interleukins for cancer immunotherapy
2022
Delivery technologies for cancer immunotherapy
2019 Standout
Phosphorylation by Casein Kinase I Promotes the Turnover of the Mdm2 Oncoprotein via the SCFβ-TRCP Ubiquitin Ligase
2010 StandoutNobel
Blinded by the Light: The Growing Complexity of p53
2009 Standout
Protein quality control and degradation in cardiomyocytes
2008
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
2018
ROCK inhibition with Y27632 promotes the proliferation and cell cycle progression of cultured astrocyte from spinal cord
2012
Oxygen sensing and hypoxia signalling pathways in animals: the implications of physiology for cancer
2013 StandoutNobel
p21 in cancer: intricate networks and multiple activities
2009 Standout
Breaking the chains: structure and function of the deubiquitinases
2009 Standout
3D bioprinting of tissues and organs
2014 Standout
Brown adipose tissue thermogenic adaptation requires Nrf1-mediated proteasomal activity
2018 StandoutNobel
Adult Neurogenesis in the Mammalian Brain: Significant Answers and Significant Questions
2011 Standout
Intrinsic disorder drives N-terminal ubiquitination by Ube2w
2014 StandoutNobel
Discovery of an oncogenic activity in p27Kip1that causes stem cell expansion and a multiple tumor phenotype
2007
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
Cell cycle, CDKs and cancer: a changing paradigm
2009 Standout
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
2016
CDK Inhibitors: Cell Cycle Regulators and Beyond
2008
Driving CAR T-cells forward
2016
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
2019
Deregulated proteolysis by the F-box proteins SKP2 and β-TrCP: tipping the scales of cancer
2008
PCNA-dependent regulation of p21 ubiquitylation and degradation via the CRL4Cdt2 ubiquitin ligase complex
2008
De novo design of tyrosine and serine kinase-driven protein switches
2021 StandoutNobel
The Age of Crosstalk: Phosphorylation, Ubiquitination, and Beyond
2007
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
2017 Standout
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Susceptibility of p53 Unstructured N Terminus to 20 S Proteasomal Degradation Programs the Stress Response
2009
Ubiquitin- and ATP-Independent Proteolytic Turnover of p21 by the REGγ-Proteasome Pathway
2007
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
2020 Standout
Controlled Synthesis of Polyubiquitin Chains
2005
DDB2 decides cell fate following DNA damage
2009
Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function
2018
Chemicals from lignin: an interplay of lignocellulose fractionation, depolymerisation, and upgrading
2018 Standout
In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism
2023 StandoutNobel
Synergistic enzymatic and microbial lignin conversion
2015
Chimeric antigen receptor–modified T cells: CD19 and the road beyond
2018
Cytokine Storm
2020 Standout
The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation
2005
Classification of Intrinsically Disordered Regions and Proteins
2014 Standout
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
2018 Standout
Ionizable lipid nanoparticles for in utero mRNA delivery
2021 StandoutNobel
Recognition and Processing of Ubiquitin-Protein Conjugates by the Proteasome
2009
Chimeric Antigen Receptor Therapy
2018 Standout
IL-6/IFN-γ double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro
2022
Cancer Genome Landscapes
2013 StandoutScience
BIMEL, an intrinsically disordered protein, is degraded by 20S proteasomes in the absence of poly-ubiquitylation
2011
Ubiquitination of p21Cip1/WAF1 by SCFSkp2: Substrate Requirement and Ubiquitination Site Selection
2005
DDB1 is essential for genomic stability in developing epidermis
2007
The Ubiquitin Code
2012 Standout
Circadian control of XPA and excision repair of cisplatin-DNA damage by cryptochrome and HERC2 ubiquitin ligase
2010 StandoutNobel
CAR T cell immunotherapy for human cancer
2018 StandoutScience
Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function
2021
Regulation of Mammalian Autophagy in Physiology and Pathophysiology
2010 Standout
N‐Carboxyanhydride Polymerization of Glycopolypeptides That Activate Antigen‐Presenting Cells through Dectin‐1 and Dectin‐2
2018 StandoutNobel
Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma
2018
Works of Xueyan Chen being referenced
Testing the importance of p27 degradation by the SCF skp2 pathway in murine models of lung and colon cancer
2006
Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes
2015
Fasudil Hydrochloride Hydrate, a Rho-Kinase Inhibitor, Suppresses 5-Hydroxytryptamine-Induced Pulmonary Artery Smooth Muscle Cell Proliferation via JNK and ERK1/2 Pathway
2008
N-Acetylation and Ubiquitin-Independent Proteasomal Degradation of p21Cip1
2004
Ubiquitin-Independent Degradation of Cell-Cycle Inhibitors by the REGγ Proteasome
2007
Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin
2013
A pathway in quiescent cells that controls p27Kip1 stability, subcellular localization, and tumor suppression
2006
Multipotency of purified, transplanted globose basal cells in olfactory epithelium
2004
Immunotherapy with CD19-specific chimeric antigen receptor (CAR)-modified T cells of defined subset composition.
2015
Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib
2017
Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia
2015
Correction: Comparative Genomic Analysis of the Endosymbionts of Herbivorous Insects Reveals Eco-Environmental Adaptations: Biotechnology Applications
2013
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
2017
Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
2016
Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
2017
Rate of durable complete response in ALL, NHL, and CLL after immunotherapy with optimized lymphodepletion and defined composition CD19 CAR-T cells.
2016